The Performance of Multi-tracer Multimodality PET in Lymphoma

Peking University Cancer Hospital & Institute

Status: Enrolling

Conditions: Positron-Emission Tomography

Study type: Observational

Funder types: Other

Identifiers

NCT05004961

XW-MMPET-001

Details and patient eligibility

About

Investigating the performance of Multi-tracer Multimodality PET in lymphoma

Full description

In this study investigators evaluated Nodal and Extranodal Lymphoma Lesions uptake by different molecular probe such as FDG, FAPI-04 via multimodality PET (PET/CT and PET/MR). Our Previous studies have shown that uptake of FAPI-04 on PET may be an indicator of lymphoma lesions. The combination of PET with CT/MR allows for depicting metabolic, functional and morphological properties of tumor lesions at the same time, which is therefore an alternative attractive pairing for diagnosis, staging and prognosis of lymphoma.

Enrollment: 200 estimated patients

Sex: All

Ages: 15 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• pathologically diagnosed as lymphoma;
• Written informed consent for receiving FAPI-04 PET examinations.
• cancer planned chemotherapy or immunotherapy scheme.
• expected survival ≥ 12 weeks

Exclusion criteria

• cannot lie supine for half an hour;
• refuse to join the clinical researcher;
• severe liver or kidney dysfunction
• pregnancy or lactation